FDA Chills on Brain Temp Gadgets – Literally
Published Date: 4/30/2026
Rule
Summary
The FDA is officially putting brain temperature measurement systems into Class II, meaning they’ll follow special safety rules but face fewer hurdles than before. This change helps make sure these devices are safe and effective while speeding up patient access to cool new tech. The new classification is effective April 30, 2026, but has been in effect since March 29, 2022, so manufacturers should be ready to follow the updated rules.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Device moved to Class II
The FDA officially classified brain temperature measurement systems as Class II (special controls). This change is effective April 30, 2026, and the classification has been applicable since March 29, 2022; the Agency says this will enhance patient access and reduce regulatory burdens compared with an automatic Class III assignment.
Must meet specific special controls
Manufacturers must meet detailed special controls for brain temperature measurement systems, including in vivo and non‑clinical performance testing, electrical/thermal/mechanical/electromagnetic testing, software verification/validation and hazard analysis, biocompatibility, usability evaluation, and specific labeling requirements. These controls are codified at 21 CFR 882.1565 and are required for a device to fall within Class II.
Premarket 510(k) notification required
FDA states that brain temperature measurement systems are subject to premarket notification under section 510(k) of the FD&C Act and that FDA has not determined them to be 510(m) exempt. If you intend to market one, you must submit a 510(k) premarket notification.
De Novo creates predicate for future devices
FDA notes that classifying this device via the De Novo process allows the brain temperature measurement system to serve as a predicate for future devices, enabling other sponsors to use the less burdensome 510(k) pathway when marketing substantially equivalent devices. This can make it easier for subsequent device makers to bring similar products to market.
Labeling must include safety warnings
Labeling for these devices must include instructions for use and specific warnings, such as a statement that the device is not intended to measure core body temperature and that an independent thermometer should be used for core temperature. Labels must also list conditions that may affect accuracy, skin‑integrity risks, limitations for diagnosis or therapy, and summaries of in vivo testing and any observed adverse events.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-08424 — Medical Devices; Radiology Devices; Classification of the Radiation Therapy Marking Device
The FDA is officially putting radiation therapy marking devices into Class II, meaning they’ll have special safety rules but less red tape than before. This change helps make sure the devices are safe and effective while making it easier for patients to get new, helpful tech. The new rules took effect on April 30, 2026, but the classification has been in place since December 10, 2021, so manufacturers should already be on board.
Next: 2026-08426 — Medical Devices; Cardiovascular Devices; Classification of the Laser-Powered Inferior Vena Cava Filter Retrieval Catheter
The FDA is officially classifying the laser-powered inferior vena cava filter retrieval catheter as a Class II device, meaning it has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative medical tool faster and ensures it’s safe and effective. The new classification is effective April 30, 2026, and could save time and money for makers and users alike.